osteogenic differentiation

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide (Macamide Impurity 14) induces osteogenic differentiation and subsequent bone formation of mesenchymal stem cells by activating the canonical Wnt/β-catenin signaling pathway, making it useful for osteoporosis research.

L-Ascorbic acid 2-phosphate magnesium (2-Phospho-L-ascorbic acid magnesium) functions as an antioxidant and stimulates hepatocyte growth factor (HGF) production. This long-acting vitamin C derivative promotes collagen formation and expression.

L-ascorbic acid 2-phosphate (Vitamin C phosphate) is a stable and long-lasting vitamin C derivative that stimulates collagen formation and has potential antioxidant capacity. L-ascorbic acid 2-phosphate is commonly used to promote osteogenic differentiation of human adipose stem cells (hASCs) in cell culture by increasing alkaline phosphatase (ALP) activity and runt-related transcription factor-2-DNA(runx2A) expression.

L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is utilized in biocatalytic dephosphorylation for electric power generation and electrochemical detection assays.

Icariside I (Lcariside I) is isolated from Epimedium herb. It can stimulate osteogenic differentiation of BMSCs and inhibit bone resorption activity of osteoclasts.

MC3343, a DNMT inhibitor with IC50 values of 5.7 μM for DNMT1 and 1.7 μM for DNMT3a, affects tumor proliferation by blocking osteosarcoma cells in the G1 or G2/M phase and induces osteogenic differentiation by specifically re-expressing genes that regulate this physiological process, and is able to show synergistic effects in combination with adriamycin and cisplatin (CDDP).

MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).

CW 008 is an agonist of the cAMP/PKA/CREB pathway, promoting osteogenic differentiation of bone marrow-derived mesenchymal stem cells (MSCs), inhibiting leptin secretion, and enhancing alkaline phosphatase (ALP) activity. It is also regarded as a PKA activator in experimental studies.

OD36 is a selective and potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 inhibits ALK2 signaling and osteogenic differentiation (KD: 37 nM), and binds efficiently to the ALK2 kinase ATP pocket.

Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) acts as a dual regulator of cell differentiation, promoting osteoblast differentiation while inhibiting osteoclast differentiation. It enhances osteogenic differentiation and alkaline phosphatase activity in human mesenchymal stem cells (hMSCs), and suppresses RANKL-activated osteoclastogenesis in RAW264.7 cells.

Astragaloside II (Astrasieversianin VIII) is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

Astragaloside I (Cyclosieversioside B) is a natural product isolated from Astragalus membranaceus. It can stimulate osteoblast differentiation through the Wnt/β-catenin signaling pathway and can be used to study osteogenic activity.

1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. 2. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. 3. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.

Bimekizumab is a humanised monoclonal antibody targeting IL17A/IL17F, capable of reducing IL17A/IL17F levels and blocking inflammation-driven osteoblast differentiation. It is applicable for investigating psoriasis and arthritis.

BMP2-derived peptide, encompassing amino acids 73 to 92 of BMP-2, induces osteogenic differentiation in bone marrow stromal cells (BMSCs) and augments bone regeneration [1].

Astragaloside I (Standard) is a reference standard for research and analysis in studies involving Astragaloside I. Astragaloside I (Cyclosieversioside B) is a natural product isolated from Astragalus membranaceus. It can stimulate osteoblast differentiation through the Wnt/β-catenin signaling pathway and can be used to study osteogenic activity.

Astragaloside II (Standard) is a reference standard for research and analysis in studies involving Astragaloside II. Astragaloside II (Astrasieversianin VIII) is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

Withanolide B (Standard) is a reference standard for research and analysis in studies involving Withanolide B. Withanolide B, a natural product isolated from Withania somnifera Dunal, promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (hBMSCs) via the ERK1/2 and Wnt/β-catenin signalling pathways, thereby enhancing bone healing. Withanolide B exhibits affinity for the catalytic domain of PARP-1.

Neoeriocitrin (Standard) is a reference standard for research and analysis in studies involving Neoeriocitrin. Neoeriocitrin is a natural product isolated from Drynaria Rhizome, shows activity on proliferation and osteogenic differentiation in MC3T3-E1. Neoeriocitrin is a potent acetylcholinesterase (AChE) inhibitor.

Curculigoside (Standard) is a reference standard for research and analysis in studies involving Curculigoside. 1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. 2. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. 3. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.

Icariside I (Standard) is a reference standard for research and analysis in studies involving Icariside I. Icariside I (Lcariside I) is isolated from Epimedium herb. It can stimulate osteogenic differentiation of BMSCs and inhibit bone resorption activity of osteoclasts.

Neoeriocitrin is a natural product isolated from Drynaria Rhizome, shows activity on proliferation and osteogenic differentiation in MC3T3-E1. Neoeriocitrin is a potent acetylcholinesterase (AChE) inhibitor.

Withanolide B, a natural product isolated from Withania somnifera Dunal, promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (hBMSCs) via the ERK1/2 and Wnt/β-catenin signalling pathways, thereby enhancing bone healing. Withanolide B exhibits affinity for the catalytic domain of PARP-1.

7,4'-Dihydroxy-8-methylflavan can significantly promote mesenchymal stem cells (MSCs) osteogenic differentiation by increasing the levels of alkaline phosphatase (ALP) activity. 7,4'-Dihydroxy-8-methylflavan also has free radical scavenging properties.